Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). $17 million payment settles all disputes with Grünenthal, including Nucynta patent litigation.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- $17 million payment settles all disputes with Grünenthal, including Nucynta patent litigation
- Grünenthal License terminated, eliminating future royalty obligations on Nucynta Products
- Grünenthal assigned certain Nucynta-related patents to Collegium, strengthening product rights
- Grünenthal filed to dismiss the patent infringement lawsuit, reducing litigation overhang
- Consent Agreement remains effective except for the defined Territory termination
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.